Share on StockTwits

Shares of Omnicell (NASDAQ:OMCL) have received a consensus recommendation of “Buy” from the nine brokerages that are covering the stock, American Banking & Market News reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $30.83.

Omnicell (NASDAQ:OMCL) opened at 26.79 on Wednesday. Omnicell has a 52 week low of $20.88 and a 52 week high of $30.33. The stock has a 50-day moving average of $27.75 and a 200-day moving average of $27.36. The company has a market cap of $980.6 million and a price-to-earnings ratio of 37.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.30 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.29 by $0.01. The company had revenue of $105.10 million for the quarter, compared to the consensus estimate of $103.23 million. During the same quarter in the prior year, the company posted $0.27 earnings per share. The company’s quarterly revenue was up 12.2% on a year-over-year basis. Analysts expect that Omnicell will post $1.23 EPS for the current fiscal year.

A number of research firms have recently commented on OMCL. Analysts at Topeka Capital Markets reiterated a “buy” rating on shares of Omnicell in a research note on Tuesday, July 29th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Omnicell in a research note on Thursday, May 29th. They now have a $28.00 price target on the stock.

Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.